U.S. Smart Respiratory Care Devices Market

Market Outlook

By 2032, the U.S. Smart Respiratory Care Devices Market is projected to reach approximately USD 17.46 billion, expanding at a CAGR of 14.28% during the forecast period 2027–2032. The market was valued at USD 7.84 billion in 2026, following expansion from approximately USD 5.30 billion in 2023, USD 6.00 billion in 2024, and USD 6.86 billion in 2025. Historical analysis covers 2023–2025, and all monetary values in this report are expressed in USD billions.

The market represents one of the most strategically important intersections between respiratory medical devices, home healthcare, connected therapeutics, remote patient monitoring, and digital clinical workflow. Unlike conventional respiratory equipment, smart respiratory care devices incorporate connectivity, sensors, cloud-based patient management, automated therapy adjustment, adherence monitoring, remote diagnostics, algorithm-supported decision-making, or digitally enabled clinician oversight.

The addressable ecosystem includes smart positive airway pressure systems, connected oxygen concentrators, connected ventilators and non-invasive ventilation devices, smart inhaler technologies, digitally enabled nebulizers, connected spirometry systems, pulmonary function monitoring devices, and associated remote management platforms. Pure pharmaceutical revenue, conventional non-connected respiratory disposables, standard inhalers without digital functionality, and consumer-only wellness applications are outside the core market definition.

Demand is being supported by the scale of respiratory disease in the United States. Asthma affects tens of millions of Americans, while chronic obstructive pulmonary disease remains a major cause of mortality, disability, emergency utilization, and healthcare spending. An aging U.S. population further increases the addressable pool for COPD management, oxygen therapy, sleep-disordered breathing treatment, chronic respiratory failure management, and home-based pulmonary monitoring.

The commercial opportunity is moving beyond hardware replacement toward connected respiratory ecosystems. Hospitals, pulmonology practices, sleep centers, durable medical equipment suppliers, payers, and integrated delivery networks increasingly value devices capable of generating actionable data after the patient leaves the facility. As a result, manufacturers are competing not only on pressure delivery, oxygen output, aerosolization performance, ventilation modes, or measurement accuracy, but also on connectivity reliability, patient engagement, therapy adherence, data interoperability, cybersecurity, clinician workflow, and reimbursement compatibility.

The transition from episodic respiratory treatment to continuous disease management will be the most important structural driver through 2032. Smart devices that identify deteriorating patients earlier, document adherence, reduce unnecessary clinical visits, simplify DME management, and enable intervention before hospitalization are positioned to capture disproportionate value.

Introduction

According to the U.S. Smart Respiratory Care Devices Market Report, the market is entering a period in which the clinical value of respiratory hardware is increasingly determined by what happens around the device rather than by the device alone.

Traditional respiratory care has historically been fragmented across physician offices, sleep laboratories, hospitals, DME suppliers, pharmacies, and the patient’s home. Data generated in one setting frequently did not follow the patient efficiently into another. Smart respiratory technologies are changing this model by converting respiratory equipment into continuously connected points of care.

This transition is particularly relevant to the United States because of its large chronic respiratory disease population, mature DME infrastructure, broad use of PAP therapy, substantial Medicare population, high smartphone penetration, advanced hospital IT infrastructure, and growing reimbursement pathways for remote physiological monitoring.

The clinical need is substantial. More than 27 million Americans were living with current asthma based on recent national surveillance, while millions more have diagnosed COPD. COPD prevalence rises sharply with age, making demographic aging directly relevant to demand for connected oxygen therapy, non-invasive ventilation, remote pulse oximetry, spirometry, and chronic respiratory monitoring. Respiratory diseases also frequently overlap with cardiovascular disease, obesity, sleep apnea, diabetes, and frailty, making connected longitudinal management increasingly valuable.

Sleep-disordered breathing represents another important demand pool. Smart PAP systems have already moved well beyond basic airflow generation. Modern platforms can capture therapy usage, pressure characteristics, mask leakage, respiratory events, adherence patterns, and other parameters and make these data available to patients, clinicians, and equipment providers. Large cloud-connected installed bases have demonstrated that respiratory care can be managed at population scale rather than through individual device checks.

Hospital economics are also reshaping procurement. Health systems increasingly evaluate respiratory technologies according to their ability to reduce ICU burden, facilitate step-down care, shorten hospitalization, support earlier discharge, lower readmission risk, and extend specialist oversight into the home. The strategic value of connectivity therefore rises when device data can support respiratory therapists, sleep specialists, pulmonologists, care coordinators, and DME operators without adding excessive administrative work.

Between 2027 and 2032, competitive advantage will increasingly depend on the ability to combine clinically validated hardware with scalable digital infrastructure. Companies that remain focused only on mechanical device performance will face stronger competition from companies capable of supporting the entire pathway from diagnosis and therapy initiation to adherence, monitoring, intervention, and long-term outcomes documentation.

Key Market Drivers: What’s Fueling the U.S. Smart Respiratory Care Devices Market Boom?

The first major driver is the persistent burden of asthma and COPD. Current asthma affects approximately 27.8 million Americans, including roughly 23.0 million adults and 4.8 million children. For manufacturers, this creates a substantial population for connected inhalation devices, smart nebulizers, home spirometry, adherence monitoring, and digital disease-management technologies. The opportunity is especially important among patients with uncontrolled disease, recurrent exacerbations, poor medication adherence, or incorrect inhaler technique.

COPD creates an equally important commercial base. Diagnosed COPD affects a meaningful share of the adult population and becomes substantially more prevalent among older adults. The disease is associated with more than 140,000 U.S. deaths annually in recent national data and approximately USD 24 billion in annual medical costs among adults aged 45 and older. These economics create incentives for technologies capable of detecting deterioration earlier, supporting oxygen therapy, monitoring symptoms, improving ventilation management, and reducing avoidable emergency or inpatient care.

The second major driver is the migration of respiratory care toward the home. Home oxygen therapy, PAP therapy, nebulization, non-invasive ventilation, post-discharge monitoring, and selected pulmonary diagnostics can increasingly be managed outside acute-care environments. For payers and health systems, moving appropriate respiratory care to the home can lower facility costs. For patients, it can reduce travel and improve continuity. For device companies, the shift expands the importance of usability, remote troubleshooting, automatic data transmission, battery life, compact form factors, and digital service models.

The third driver is remote physiological monitoring. Medicare broadly recognizes remote monitoring using connected medical devices that automatically transmit physiological information when applicable coverage criteria are met. Respiratory care is naturally aligned with this infrastructure because relevant variables can include oxygen saturation, respiratory rate, airflow, treatment usage, pulmonary function, sleep-related respiratory events, and therapy adherence. Connected respiratory manufacturers able to integrate device data into reimbursable clinical workflows are better positioned than companies offering isolated consumer applications.

The fourth driver is the scale of obstructive sleep apnea and PAP therapy. Sleep therapy is one of the most mature connected-device categories in healthcare. Cloud-linked PAP platforms already allow providers and DMEs to monitor large patient populations remotely. By 2026, one major respiratory device manufacturer reported more than 35 million patients using its cloud-connected device ecosystem, illustrating how respiratory therapy has become one of the largest operational deployments of connected medical technology.

The fifth driver is the aging U.S. population. More than 61 million Americans were aged 65 or older in 2024. Older adults carry disproportionately high burdens of COPD, sleep apnea, hypoxemia, respiratory muscle weakness, multimorbidity, and post-acute care requirements. This demographic base supports demand for connected oxygen concentrators, NIV systems, monitoring equipment, smart PAP platforms, and simplified interfaces designed for home use.

The sixth driver is provider labor pressure. Respiratory therapists, sleep specialists, nurses, pulmonary practices, and DME organizations must manage larger patient populations without proportionate increases in clinical staff. Smart respiratory systems create economic value when they automate adherence review, triage exception cases, identify equipment issues, prioritize deteriorating patients, or reduce manual device downloads.

The seventh driver is the growing importance of data in payer and provider contracting. Connected devices can provide objective evidence of usage, therapy persistence, device performance, and selected patient outcomes. These data are increasingly important for demonstrating medical necessity, improving DME asset utilization, supporting reimbursement documentation, and building value-based arrangements.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in smart respiratory care is shifting from simple Bluetooth connectivity toward clinically meaningful intelligence. Connecting a device to a smartphone is no longer sufficient differentiation. The strongest platforms are being designed to capture high-quality information, transform those data into actionable insights, and deliver information to the appropriate user without increasing workflow complexity.

Connected inhaler technology illustrates this progression. Digital sensors can record actuation events, identify usage patterns, support reminders, and increasingly evaluate inhalation technique. In 2025, the FDA cleared a Bluetooth-enabled add-on sensor for selected metered-dose inhalers that can transform conventional inhalers into connected devices. This type of technology is important because uncontrolled asthma and COPD may reflect not only pharmacological failure but also poor adherence or incorrect administration.

Smart PAP systems are evolving toward more personalized therapy. Connected platforms enable remote setup, adherence review, mask and leakage assessment, therapy optimization, patient coaching, and DME fleet management. Large longitudinal datasets also create opportunities for predictive analytics that may identify patients at risk of abandoning therapy before they become non-adherent.

Oxygen therapy is becoming more digitally enabled as portable oxygen concentrators incorporate Bluetooth connectivity, mobile applications, device-status monitoring, battery information, usage data, maintenance alerts, and support features. For DME providers, remote visibility can reduce unnecessary service calls and improve equipment management. For patients, connected systems can simplify troubleshooting and reduce uncertainty about battery life, flow settings, and maintenance requirements.

Ventilation technology is increasingly incorporating advanced sensors, automated modes, adaptive pressure support, alarm intelligence, high-resolution data capture, and remote connectivity. This is particularly important in chronic respiratory failure, neuromuscular disease, COPD, and complex home ventilation, where changes in therapy requirements may occur gradually.

Digital spirometry is another significant growth area. Traditional pulmonary function testing remains essential, but compact connected spirometers are expanding access to serial lung-function measurements. The highest-value use cases are expected to involve clinically supervised monitoring rather than unsupervised consumer testing, particularly where trends in forced expiratory volume or other pulmonary parameters can influence treatment decisions.

Artificial intelligence will increasingly operate as a cross-market layer. The most commercially relevant applications will involve patient prioritization, exacerbation-risk identification, signal quality assessment, adherence prediction, respiratory-event classification, automated reporting, and clinical workflow triage. The winning systems are unlikely to replace respiratory clinicians; instead, they will enable clinicians to identify which patients require attention first.

Segmentation Insights

The U.S. Smart Respiratory Care Devices Market is segmented on the basis of product type, connectivity and intelligence technology, application, end user, business and deployment model, and geography.

By Product Type

Smart PAP and Sleep Therapy Devices

Smart PAP and sleep therapy devices represented approximately USD 2.58 billion, or 32.9% of the U.S. market in 2026, making this the largest product segment.

The category includes connected CPAP, APAP, bilevel PAP, cloud-linked sleep therapy devices, digitally enabled therapy management systems, and integrated adherence platforms. Its leadership reflects a mature reimbursement structure, large treated patient population, recurring device replacement cycle, and early adoption of remote monitoring compared with most other respiratory categories.

The commercial model is particularly attractive because value extends beyond the physical PAP unit. Manufacturers can build durable relationships through cloud software, patient applications, masks, accessories, provider workflows, and DME integration. Through 2032, competition will increasingly center on patient retention and therapeutic outcomes rather than pressure-delivery hardware alone.

Smart Oxygen Therapy Devices

Smart oxygen therapy devices accounted for approximately USD 1.36 billion, representing 17.3% of the 2026 market.

This segment includes connected portable oxygen concentrators, smart stationary concentrators, oxygen systems with mobile applications, device-performance monitoring, battery intelligence, maintenance alerts, and digitally supported DME services. Demand is closely linked to COPD, chronic hypoxemia, interstitial lung disease, post-acute respiratory care, and the large Medicare population.

Portable systems are gaining strategic importance because mobility is a major determinant of patient quality of life. Connectivity can also create operational savings for suppliers by reducing avoidable technician visits and improving preventive maintenance.

Connected Ventilation and Non-Invasive Ventilation Devices

Connected ventilation and NIV represented approximately USD 1.12 billion, or 14.3% of market value in 2026.

The segment covers digitally enabled hospital ventilators, home mechanical ventilation systems, bilevel ventilatory support, non-invasive ventilators, adaptive respiratory support devices, and connected clinical management platforms. Hospital systems prioritize advanced ventilation technologies based on clinical reliability, patient safety, alarm performance, interoperability, infection-control considerations, and respiratory therapist workflow.

The home ventilation opportunity is increasingly important as medically complex patients receive longer-term respiratory support outside hospitals. Remote device monitoring can allow clinicians and DME organizations to identify adherence issues, circuit problems, changing respiratory requirements, or equipment alarms without waiting for an in-person assessment.

Connected and Smart Inhalers

Connected inhalers generated approximately USD 1.01 billion, accounting for 12.9% of the 2026 market.

This category includes integrated digital inhalers, sensor-enabled inhalers, connected add-on devices for metered-dose inhalers, adherence-monitoring systems, technique-assessment technologies, and related patient applications. The underlying addressable population is substantial because current asthma alone affects more than 27 million Americans, while inhaled therapy is also central to COPD management.

Growth will be driven less by novelty and more by evidence that connected inhalers can improve adherence, distinguish poor technique from pharmacological treatment failure, and identify patients with excessive rescue medication use.

Digital Spirometry and Pulmonary Monitoring Devices

Digital spirometry and connected pulmonary monitoring represented approximately USD 0.96 billion, or 12.2% of the market in 2026.

The segment includes connected spirometers, handheld pulmonary function devices, respiratory-rate monitoring systems, remote lung-function platforms, and digitally enabled physiological monitoring used in chronic respiratory care.

The value proposition is strongest when serial measurements are incorporated into an established clinical program. Pulmonologists and health systems are increasingly interested in tools that allow patients to be monitored between appointments, particularly following exacerbations or medication changes.

Smart Nebulizers

Smart nebulizers represented approximately USD 0.81 billion, equivalent to 10.3% of market revenue in 2026.

These systems include digitally enabled nebulizers, dose-tracking nebulization devices, electronically controlled aerosol-delivery platforms, portable connected nebulizers, and treatment-management applications. Pediatric asthma, severe asthma, COPD, cystic fibrosis, bronchiectasis, and selected specialty drug-delivery requirements support demand.

The strongest growth opportunities will be in systems that combine consistent aerosol performance with portability, adherence data, treatment confirmation, and simpler cleaning or maintenance.

By Connectivity and Intelligence Technology

Cloud and Wi-Fi Connected Systems

Cloud and Wi-Fi connected respiratory systems accounted for approximately USD 2.47 billion, or 31.5% of the 2026 market. The segment is led by PAP therapy, connected ventilation, enterprise respiratory monitoring, and clinician-facing platforms. Cloud architecture is increasingly essential for managing large patient populations, supporting remote configuration, and allowing centralized review across health systems and DME networks.

Bluetooth and Mobile Application Connectivity

Bluetooth and application-connected products generated approximately USD 1.89 billion, representing 24.1% of the market in 2026. Portable oxygen concentrators, smart inhalers, compact spirometers, nebulizers, and patient-facing therapy devices frequently use Bluetooth because it supports low-power connectivity with smartphones. Future differentiation will depend on whether the application generates clinically useful information rather than merely displaying device status.

Cellular and Remote Telemetry

Cellular and remote telemetry technologies accounted for approximately USD 1.36 billion, or 17.3% of the 2026 market. Embedded connectivity is valuable in populations where reliance on patient Wi-Fi or smartphone pairing could reduce data continuity. DME organizations and home-care providers may favor cellular connectivity for higher-acuity patients because it simplifies setup and improves automatic transmission.

AI and Algorithm-Enabled Respiratory Systems

AI and algorithm-enabled technologies represented approximately USD 1.25 billion, equivalent to 15.9% of market value in 2026. Applications include automated PAP adjustment, ventilation algorithms, respiratory-event detection, adherence-risk identification, exacerbation prediction, signal interpretation, and workflow prioritization. This segment is expected to gain share rapidly through 2032 as intelligence becomes embedded across hardware categories.

Embedded Sensor and IoT Technologies

Embedded sensor and IoT-focused technologies represented approximately USD 0.87 billion, or 11.1% of the 2026 market. Flow sensors, pressure sensors, usage sensors, oxygen-monitoring components, environmental sensors, accelerometers, and dose-detection technologies form the underlying infrastructure of smart respiratory products. Sensor accuracy and calibration remain important because poor data quality undermines every downstream digital application.

By Application

Sleep Apnea Management

Sleep apnea management was the largest application, representing approximately USD 2.72 billion and 34.7% of 2026 revenue. Smart PAP systems, adherence platforms, sleep-monitoring interfaces, cloud-connected therapeutic devices, and remotely managed bilevel therapy dominate this application. Its scale reflects established clinical pathways and the large installed base of connected PAP equipment.

COPD Management

COPD represented approximately USD 1.68 billion, or 21.4% of the market in 2026. Relevant devices include oxygen concentrators, NIV systems, connected inhalers, smart nebulizers, pulse-oximetry-linked monitoring, spirometry, and post-exacerbation monitoring. COPD’s high mortality, hospitalization burden, and annual medical cost make it one of the strongest clinical targets for remote respiratory management.

Asthma Management

Asthma accounted for approximately USD 1.18 billion, representing 15.1% of 2026 market value. Connected inhalers, adherence sensors, smart nebulizers, portable spirometry, and digital monitoring tools are central to this segment. With approximately 42% of people with current asthma in recent national data reporting at least one attack during the preceding year, technologies capable of improving treatment consistency and identifying deteriorating control have substantial clinical relevance.

Chronic Respiratory Failure

Chronic respiratory failure contributed approximately USD 0.91 billion, or 11.6% of the market in 2026. The application includes home ventilation, NIV, connected oxygen therapy, advanced respiratory monitoring, and high-acuity home-care technologies. The patient population is smaller than asthma or COPD but generates higher device value per patient and requires more intensive clinical support.

Post-Acute and Remote Respiratory Monitoring

Post-acute and remote monitoring represented approximately USD 0.76 billion, equivalent to 9.7% of 2026 market revenue. Hospitals are increasingly interested in monitoring selected patients after respiratory hospitalization, pneumonia, COPD exacerbation, surgery, or acute hypoxemic illness. Commercial viability depends on connecting device data with a defined clinical response pathway rather than generating information without intervention capacity.

Other Respiratory Applications

Other applications generated approximately USD 0.59 billion, or 7.5% of the 2026 market. These include bronchiectasis, cystic fibrosis support, neuromuscular respiratory management, interstitial lung disease, selected pediatric respiratory conditions, pulmonary rehabilitation support, and specialty aerosol therapy.

By End User

Homecare Patients and Durable Medical Equipment Providers

Homecare and DME represented approximately USD 3.28 billion, accounting for 41.8% of the market in 2026. It is the dominant end-user environment because PAP, oxygen, home ventilation, nebulization, and chronic respiratory monitoring are increasingly managed outside hospitals. Smart technology is valuable to DME companies because remote visibility can improve adherence management, asset utilization, troubleshooting, documentation, and resupply coordination.

Hospitals and Integrated Health Systems

Hospitals and health systems generated approximately USD 1.86 billion, or 23.7% of 2026 revenue. Demand covers smart ventilation, respiratory monitoring, digitally integrated oxygen therapy, connected pulmonary diagnostics, and technology used to transition patients safely into post-acute care. Procurement decisions increasingly consider interoperability, cybersecurity, service reliability, and total respiratory-care workflow rather than hardware acquisition cost alone.

Sleep Centers and Pulmonology Practices

Sleep centers and pulmonary practices accounted for approximately USD 1.18 billion, representing 15.1% of the market in 2026. These providers are central to PAP therapy management, spirometry, connected inhaler programs, chronic respiratory surveillance, and digital adherence management. Technologies that reduce staff time per patient while maintaining clinical oversight are particularly attractive.

Ambulatory and Outpatient Care Settings

Ambulatory centers accounted for approximately USD 0.55 billion, or 7.0% of 2026 revenue. Outpatient pulmonary clinics, urgent-care networks, ambulatory diagnostic settings, and specialist practices are adopting compact respiratory monitoring and diagnostic technologies as care moves away from hospital campuses.

Pharmacies and Digital Distribution Channels

Pharmacy-linked and digital channels generated approximately USD 0.51 billion, representing 6.5% of market value in 2026. Their importance is greatest in smart inhaler accessories, portable nebulization, selected oxygen products, connected monitoring, replacement devices, and patient-facing respiratory technologies. Regulatory status and reimbursement determine how far direct-to-consumer distribution can extend.

Skilled Nursing and Long-Term Care

Skilled nursing facilities and long-term-care organizations represented approximately USD 0.46 billion, or 5.9% of the 2026 market. Aging residents frequently require oxygen, PAP therapy, nebulization, chronic respiratory surveillance, or non-invasive ventilatory support. Connected systems can support staff by identifying therapy non-adherence and equipment issues more rapidly.

By Business and Deployment Model

Device Plus Cloud Platform

Integrated device-and-cloud platforms generated approximately USD 3.10 billion, representing 39.5% of the market in 2026. This is the dominant model because it allows manufacturers to combine hardware revenue with provider software, patient applications, remote management, and recurring ecosystem participation.

DME Rental and Recurring Therapy Model

DME rental and recurring respiratory therapy accounted for approximately USD 1.74 billion, or 22.2% of market value in 2026. Oxygen equipment, PAP systems, and selected ventilation products frequently operate through reimbursement structures that reward reliable equipment management and therapy continuation.

Prescription Device Purchase

Prescription-linked device purchases generated approximately USD 1.22 billion, representing 15.6% of the 2026 market. This includes connected diagnostic and therapeutic products acquired through provider prescription or specialist-driven treatment pathways.

Software and RPM-Enabled Model

Software and remote-monitoring-enabled models represented approximately USD 0.95 billion, or 12.1% of market value in 2026. This category is expected to gain strategic importance as providers seek recurring revenue and scalable monitoring models. Success will depend on demonstrating that remote data review changes care rather than adding administrative workload.

Replacement and Accessory-Linked Ecosystems

Replacement, accessory, and service-linked smart respiratory revenue represented approximately USD 0.83 billion, or 10.6% of the 2026 market. Masks, sensors, batteries, interfaces, maintenance components, patient support, and recurring accessories increase customer lifetime value and can reinforce platform loyalty.

Regional Insights: Where the Market is Growing Fastest

The U.S. Smart Respiratory Care Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional differences are shaped by population size, respiratory disease prevalence, age distribution, smoking history, rurality, specialist access, DME density, Medicare exposure, academic medical-center concentration, technology adoption, and home-health infrastructure.

The South is the largest regional market, while the West is positioned to record the fastest growth through 2032. The Northeast remains an important premium-technology and clinical-evidence market, while the Midwest combines significant chronic respiratory disease burden with large integrated health systems and a strong homecare opportunity.

South

The South represented approximately USD 2.80 billion in 2026 and is projected to reach about USD 6.15 billion by 2032, representing an approximate 14.01% CAGR.

The region includes Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia and West Virginia, with the District of Columbia forming part of the broader Census South.

Its market leadership is supported by population scale, COPD burden, asthma prevalence, older adult growth, significant rural populations, major hospital systems, and extensive DME activity. Chronic respiratory disease frequently carries a substantial burden outside major metropolitan areas, increasing the need for technologies capable of moving specialist oversight into the home.

Texas is one of the most important state markets because of its large population, extensive hospital networks, major metropolitan healthcare hubs, broad DME footprint, and significant asthma population. Recent state-level surveillance identified nearly two million Texas adults with current asthma. Connected PAP, portable oxygen, pulmonary monitoring, smart inhalation, and home respiratory technologies have substantial addressable demand.

Florida combines a very large older population with high utilization of Medicare-covered respiratory services. The state is particularly important for PAP therapy, home oxygen, chronic COPD management, portable oxygen concentrators, and post-acute respiratory monitoring. Florida also provides favorable conditions for home-based technology because of the scale of retirement communities and long-term disease-management requirements.

North Carolina, Georgia, Virginia and Tennessee are increasingly attractive markets as population growth, academic medical centers, health-system consolidation, and specialty respiratory capacity expand. North Carolina reported more than 850,000 adults with current asthma in recent surveillance, while Tennessee had more than 600,000.

West Virginia illustrates the importance of disease burden rather than population size alone. Recent state surveillance placed adult current asthma prevalence at nearly 14%, one of the highest rates in the country. States with elevated chronic disease and rural access limitations provide a particularly strong use case for remote respiratory monitoring, connected oxygen management, and digitally supervised home therapy.

Alabama, Arkansas, Kentucky, Louisiana, Mississippi and Oklahoma similarly represent important markets for scalable home respiratory technologies because access to pulmonology and sleep specialists can be uneven outside metropolitan centers. Remote monitoring cannot replace specialist care, but it can reduce the frequency with which stable patients must travel for routine device checks.

West

The West represented approximately USD 1.90 billion in 2026 and is projected to reach roughly USD 4.53 billion by 2032, producing the fastest regional CAGR at approximately 15.58%.

The region includes Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington and Wyoming.

The West’s growth advantage is driven by digital-health adoption, large technology ecosystems, health-system investment in connected care, expanding populations in several states, high use of home monitoring, and strong penetration of smartphone-enabled healthcare.

California is the largest state market in the region and one of the most influential nationally. Its value comes from population scale, academic health systems, payer innovation, digital-health development, respiratory technology companies, and earlier adoption of connected medical devices. Recent surveillance identified approximately 2.7 million California adults with current asthma, providing a substantial addressable base for connected inhalation and monitoring solutions.

Arizona is an increasingly important market because rapid population growth and retirement migration expand the patient base for COPD, sleep apnea, oxygen therapy, and PAP treatment. The state’s recent adult asthma population exceeded 600,000.

Colorado is notable for strong connected-care adoption and an adult asthma prevalence above 11% in recent state data. Health systems in Colorado also have experience managing dispersed patient populations, creating favorable conditions for remote pulmonary monitoring.

Oregon and Washington have strong digital-health environments, integrated delivery networks, and relatively high adult asthma prevalence. Washington reported approximately 660,000 adults with current asthma, while Oregon’s prevalence approached 12% in recent surveillance.

Nevada and Utah are attractive growth markets because of population expansion and increasing specialist infrastructure. New Mexico, Montana, Idaho, Wyoming and Alaska represent smaller absolute markets but offer compelling remote-care use cases where distance and specialist availability can complicate conventional respiratory follow-up.

The West should gain share through 2032 as respiratory devices become more software-defined, patient-facing, remotely managed, and integrated with digital clinical workflows.

Northeast

The Northeast represented approximately USD 1.73 billion in 2026 and is projected to reach approximately USD 3.79 billion by 2032, reflecting an approximate 13.96% CAGR.

The region includes Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island and Vermont.

The Northeast is characterized by high specialist density, sophisticated academic medical centers, research-intensive hospital systems, stronger adoption of complex respiratory technologies, and rigorous evidence requirements. It may not match the South in absolute population growth, but it remains exceptionally important for clinical validation and early adoption.

New York is the largest regional state market. Recent surveillance identified approximately 1.55 million New York adults with current asthma. Large integrated systems in New York provide substantial opportunities for cloud-connected PAP, advanced ventilation, digital pulmonary diagnostics, chronic respiratory monitoring, and smart inhalation technologies.

Massachusetts has disproportionate influence because of its academic medical institutions, life-science ecosystem, digital-health infrastructure, and specialist concentration. Adult asthma prevalence was close to 12% in recent state data. Massachusetts is especially relevant for companies seeking clinical partners, real-world evidence, and technology evaluation.

New Jersey and Pennsylvania provide large respiratory patient populations and dense provider networks. These states are important for DME operations, sleep medicine, COPD management, hospital respiratory care, and pharmaceutical-device partnerships involving connected inhalation.

Maine, New Hampshire, Rhode Island and Vermont have smaller populations but relatively high asthma prevalence and aging demographics. Maine’s adult asthma prevalence exceeded 12% in recent surveillance, and Rhode Island was similarly elevated. These states strengthen the use case for connected respiratory technologies capable of extending specialist oversight beyond major urban centers.

Procurement in the Northeast is typically evidence-driven. Manufacturers seeking premium adoption must demonstrate clinical utility, interoperability, cybersecurity maturity, health-economic value, and credible support infrastructure.

Midwest

The Midwest represented approximately USD 1.41 billion in 2026 and is projected to reach approximately USD 2.99 billion by 2032, reflecting a CAGR of approximately 13.35%.

The region includes Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota and Wisconsin.

The Midwest combines large metropolitan hospital systems with substantial rural and nonmetropolitan populations. This combination creates demand for both advanced hospital respiratory technology and scalable home-care solutions.

Ohio is a major regional market and reported more than one million adults with current asthma in recent state-level surveillance. Its extensive hospital infrastructure, academic centers, pulmonary practices, and DME base support broad smart respiratory device utilization.

Illinois provides a large urban and suburban patient base centered around Chicago and other population centers. Smart PAP, respiratory monitoring, pulmonary diagnostics, oxygen therapy, and hospital ventilation represent important categories.

Michigan reported approximately 869,000 adults with current asthma and also carries substantial chronic respiratory disease burden associated with aging, smoking history, industrial exposure, and socioeconomic variation.

Indiana reported adult asthma prevalence above 11%, strengthening demand for chronic respiratory management. Wisconsin also recorded prevalence near 11%, while Minnesota remains strategically important due to its advanced medtech ecosystem and sophisticated healthcare delivery networks.

Iowa, Kansas, Nebraska, North Dakota and South Dakota are smaller device markets in absolute terms but are important for remote monitoring and home respiratory care because patient travel distances and specialist access can be challenging.

The Midwest is likely to remain the slowest-growing of the four regions, but it offers durable demand, strong integrated delivery networks, significant DME activity, and substantial need for technologies that reduce geographic barriers to respiratory management.

Key Market Players

The U.S. Smart Respiratory Care Devices Competitive Landscape is becoming increasingly platform-oriented. Hardware performance remains essential, but differentiation increasingly comes from software, remote connectivity, adherence management, clinical data, DME integration, cybersecurity, and the ability to support patients after device deployment.

Large companies benefit from installed bases, reimbursement expertise, distribution infrastructure, and hospital contracting capability. Specialized companies can still gain share by solving specific respiratory workflow problems, improving portability, digitizing inhalation therapy, or creating better monitoring and patient-engagement tools.

Some of the key players operating in the U.S. Smart Respiratory Care Devices industry are:

ResMed
Philips Respironics
Fisher & Paykel Healthcare
Inogen
Drive DeVilbiss Healthcare
React Health
Masimo
Baxter International
GE HealthCare
Medtronic
Aptar Digital Health
OMRON Healthcare
PARI Respiratory Equipment
Aerogen
Hamilton Medical

ResMed holds a particularly strong strategic position because connected sleep and respiratory care is central to its operating model. Its cloud infrastructure and large connected-patient base create network effects involving clinicians, DMEs, patients, and therapy-management data.

Philips Respironics remains an important historical respiratory technology competitor, although its U.S. position continues to be affected by regulatory remediation and restrictions related to the major CPAP, BiPAP, and ventilator recall. Competitive share in U.S. sleep therapy has consequently shifted toward alternative suppliers and created opportunities for newer entrants.

Inogen is important in portable oxygen because connectivity, mobility, battery management, and direct patient engagement increasingly influence product differentiation. Fisher & Paykel Healthcare remains relevant across respiratory humidification, interfaces, oxygen therapy, and hospital respiratory care.

Aptar Digital Health strengthens the connected-inhaler ecosystem, while PARI and Aerogen participate in advanced aerosol-delivery technologies. GE HealthCare, Baxter, Masimo, Medtronic, and Hamilton Medical are strategically important across hospital respiratory monitoring, critical-care ventilation, physiological monitoring, and integrated clinical workflows.

Competitive advantage through 2032 will depend on FDA execution, quality systems, device reliability, data interoperability, reimbursement support, DME relationships, cybersecurity, patient adherence, and evidence demonstrating that connectivity produces measurable clinical or economic improvement.

Recent Developments

Recent developments demonstrate that the smart respiratory care market is moving beyond basic device connectivity toward regulated, clinically integrated digital functionality.

In October 2025, Aptar Digital Health announced U.S. FDA 510(k) clearance for HeroTracker Sense, a Bluetooth-enabled connected add-on for selected pressurized metered-dose inhalers. The clearance is strategically important because it demonstrates a pathway for converting established inhaler platforms into digitally monitored respiratory therapies without requiring complete replacement of the underlying drug-delivery device.

In 2026, connected respiratory ecosystems continued to scale substantially. ResMed reported more than 35 million patients using cloud-connected devices on AirView and more than 12 million patients registered on myAir. The size of this installed base illustrates that smart respiratory technology is already operating at population-health scale rather than remaining a limited digital-health pilot category.

Regulatory conditions continue to reshape competition in PAP and ventilation. Following the large Philips Respironics recall, a U.S. federal consent decree entered in 2024 restricted, with limited exceptions, production and sale of certain new CPAP, BiPAP, and other devices at specified U.S. facilities until regulatory requirements are satisfied. By 2026, Philips reported substantial remediation progress, although the episode continues to influence buyer attention to quality systems, product safety, supplier concentration, and continuity of respiratory-device supply.

The reimbursement environment is also evolving. Medicare already supports remote physiological monitoring using qualifying connected medical devices for eligible chronic and acute conditions. For calendar year 2027, CMS has proposed additional changes affecting remote monitoring requirements and payment structure. Respiratory technology companies therefore need reimbursement strategies flexible enough to operate under changing RPM and remote therapy monitoring rules.

Digital health regulation is moving toward closer coordination between device authorization, evidence generation, and chronic-care reimbursement. The FDA’s 2026 Technology-Enabled Meaningful Patient Outcomes initiative reflects broader federal interest in creating scalable pathways for digital medical technologies capable of improving chronic-disease outcomes. Respiratory care is well positioned to benefit from this direction because asthma, COPD, sleep apnea, and chronic respiratory failure all require sustained management outside traditional episodic visits.

Innovation is also expanding in oxygen-delivery and respiratory-support technology. Connected portable oxygen devices increasingly allow patients and providers to view device status, battery information, flow settings, usage parameters, maintenance requirements, and support information through mobile applications. These capabilities are turning oxygen concentrators from stand-alone durable medical equipment into digitally managed home-care assets.

The broader competitive implication is that the smart respiratory market is moving toward continuous improvement cycles. Software updates, algorithms, applications, cloud infrastructure, analytics, and workflow integrations can evolve more rapidly than traditional medical hardware. Manufacturers therefore need development organizations capable of managing both conventional device lifecycles and software-driven product iterations.

Conclusion

The U.S. Smart Respiratory Care Devices Market Size & Share is positioned to expand from USD 7.84 billion in 2026 to approximately USD 17.46 billion by 2032, representing a 14.28% CAGR during 2027–2032.

Growth will be supported by the large U.S. asthma and COPD populations, aging demographics, expanding sleep-therapy demand, migration of respiratory care to the home, remote physiological monitoring, DME digitalization, connected oxygen therapy, and rising clinical demand for continuous patient visibility.

Smart PAP and sleep therapy devices currently represent the largest product category, but connected inhalers, digital pulmonary monitoring, smart nebulization, oxygen connectivity, and AI-supported respiratory management are expected to expand the market’s value pool substantially.

The commercial center of gravity is shifting from isolated respiratory hardware toward connected therapeutic ecosystems. Successful suppliers will increasingly combine a medical device, data layer, patient interface, clinician workflow, service infrastructure, and reimbursement strategy into a coherent platform.

Homecare and DME will remain the largest end-user environment because smart respiratory care naturally supports longitudinal treatment outside hospitals. At the same time, health systems will increase investment in technologies capable of supporting safer discharge, respiratory deterioration monitoring, and better integration between acute and home care.

Regionally, the South will remain the largest opportunity because of population scale, respiratory disease burden, Medicare exposure, and homecare utilization. The West is expected to grow fastest because of digital-health adoption and technology integration. The Northeast will continue to influence clinical evidence and premium adoption, while the Midwest offers substantial opportunities for connected care across mixed urban and rural populations.

At the state level, California, Texas, Florida, New York, Ohio, Pennsylvania, Illinois, North Carolina, Georgia, Michigan, Massachusetts, Arizona, Washington, Tennessee, and Virginia will remain particularly important commercial markets, while states with high asthma or COPD prevalence and limited specialist access provide additional opportunities for scalable remote respiratory care.

For companies, investors, healthcare providers, and strategic buyers evaluating the U.S. Smart Respiratory Care Devices Market, the central question is no longer whether respiratory devices will become connected. That transition is already underway. The more important questions are which connected functions meaningfully alter clinical decisions, which business models can produce recurring economic value, which technologies fit reimbursement pathways, and which manufacturers can convert respiratory data into measurable patient and provider outcomes.

The companies that succeed through 2032 will be those that combine reliable respiratory hardware with clinically relevant intelligence, strong quality systems, interoperable software, reimbursement support, evidence generation, patient-centered design, and demonstrable improvements in respiratory-care economics.